menu search

JAZZ / JAZZ Inks Deal With Werewolf to Add Oncology Candidate

JAZZ Inks Deal With Werewolf to Add Oncology Candidate
Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types. Read More
Posted: Apr 8 2022, 15:48
Author Name: Zacks Investment Research
Views: 103166

JAZZ News  

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

By Zacks Investment Research
October 26, 2023

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two more_horizontal

Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock?

By Zacks Investment Research
October 17, 2023

Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock?

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stoc more_horizontal

JAZZ or ZTS: Which Is the Better Value Stock Right Now?

By Zacks Investment Research
October 10, 2023

JAZZ or ZTS: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Zoetis (ZTS). But which of the more_horizontal

Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze

By Zacks Investment Research
September 22, 2023

Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activit more_horizontal

Why Is Jazz (JAZZ) Up 0.4% Since Last Earnings Report?

By Zacks Investment Research
September 8, 2023

Why Is Jazz (JAZZ) Up 0.4% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? more_horizontal

Pharmaceutical cannabis sales surge, clinical trials seeing broader disease focus

By Proactive Investors
August 30, 2023

Pharmaceutical cannabis sales surge, clinical trials seeing broader disease focus

The global pharmaceutical cannabis market is poised for significant growth, projected to swell by 23% by 2027, mostly from one company but with other more_horizontal

Wall Street Analysts See a 51.66% Upside in Jazz (JAZZ): Can the Stock Really Move This High?

By Zacks Investment Research
August 10, 2023

Wall Street Analysts See a 51.66% Upside in Jazz (JAZZ): Can the Stock Really Move This High?

The consensus price target hints at a 51.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly e more_horizontal

Jazz (JAZZ) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

By Zacks Investment Research
August 9, 2023

Jazz (JAZZ) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2023, it could be worth lo more_horizontal


Search within

Pages Search Results: